Fred Aslan Sells 25,500 Shares of Artiva Biotherapeutics (NASDAQ:ARTV) Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) CEO Fred Aslan sold 25,500 shares of Artiva Biotherapeutics stock in a transaction that occurred on Friday, October 17th. The stock was sold at an average price of $6.00, for a total value of $153,000.00. Following the completion of the transaction, the chief executive officer directly owned 356,721 shares in the company, valued at $2,140,326. This trade represents a 6.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Fred Aslan also recently made the following trade(s):

• On Friday, August 15th, Fred Aslan sold 25,500 shares of Artiva Biotherapeutics stock. The shares were sold at an average price of $2.73, for a total value of $69,615.00.

Artiva Biotherapeutics Trading Up 117.0%

NASDAQ:ARTV opened at $6.01 on Friday. The company has a fifty day moving average of $2.91 and a 200 day moving average of $2.44. Artiva Biotherapeutics, Inc. has a 52 week low of $1.47 and a 52 week high of $15.49.

Artiva Biotherapeutics (NASDAQ:ARTV) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.03). On average, sell-side analysts predict that Artiva Biotherapeutics, Inc. will post -4.95 EPS for the current year.

Analyst Ratings Changes

A number of analysts recently commented on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Artiva Biotherapeutics in a research note on Wednesday, October 8th. Wedbush raised their target price on shares of Artiva Biotherapeutics from $18.00 to $23.00 and gave the stock an “outperform” rating in a research report on Friday. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $18.00 target price on shares of Artiva Biotherapeutics in a research note on Friday. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Artiva Biotherapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $18.25.

Institutional Trading of Artiva Biotherapeutics

A number of hedge funds have recently modified their holdings of ARTV. Charles Schwab Investment Management Inc. increased its stake in shares of Artiva Biotherapeutics by 26.1% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 54,881 shares of the company’s stock worth $165,000 after acquiring an additional 11,355 shares in the last quarter. Ground Swell Capital LLC purchased a new stake in Artiva Biotherapeutics in the second quarter worth about $38,000. Y Intercept Hong Kong Ltd bought a new position in shares of Artiva Biotherapeutics during the second quarter valued at approximately $48,000. Bridgeway Capital Management LLC purchased a new position in shares of Artiva Biotherapeutics during the second quarter valued at approximately $53,000. Finally, Qube Research & Technologies Ltd bought a new stake in shares of Artiva Biotherapeutics in the 2nd quarter worth approximately $58,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.